Publications

Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors

Debio 0123 + Carboplatin for Patients with Advanced Solid Tumors: Safety, Preliminary Efficacy and Determination of Recommended Phase 2 Dose

Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin and etoposide in patients with small cell lung cancer that…

Theranostic targeting of CAIX in patients with clear cell renal cell carcinoma: first‑in‑human safety, imaging and dosimetry findings with [68Ga]Ga‑DPI-4452

Population PK and Exposure-Response Modeling to Support the Design of Trials with DEBIO 0123, a WEE1 Inhibitor, in Cancer Patients

CD37 is a Relevant Target for AML and MDS Treatment with Debio 1562M Antibody Drug Conjugate (ADC)

Results of a Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors –…

Exploring the content and psychometric validity of clinical outcome assessments in pancreatic ductal adenocarcinoma versus the patient reported symptoms and…

Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and…